May 2024 $50 M Private placement after listing $50 to $250 million 24
Tokai Pharmaceuticals Inc: Private sale, May 2024 × Investors in this round 24 investors had bought by the notice of May 23, 2024: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $1,617,174
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bryan Smith · Executive Officer David-Alexandre Gros · Executive Officer, Director Paul Little · Executive Officer Steven Perrin · Executive Officer, Director Allan Kirk · Director James Robinson · Director Jan Hillson · Director John McBride · Director June Lee · Director Keith Katkin · Director Walter Ogier · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Leerink Partners LLC (CRD 39011) · Boston, Massachusetts Sold in all US states, and outside the US Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, Florida Sold in CA, FL, ID, MA, ND, NV, NY, VA Remarks in the notice On the amounts: “$49,999,010.48 of common stock and pre-funded warrants sold; plus $7,989.52 assuming exercise of all pre-funded warrants.”Signed by Paul Little, Chief Financial Officer. Newest notice filed May 23, 2024. Read the notice at the SEC .
equity, options SEC May 2023 $35 M Private placement after listing $10 to $50 million 38
Tokai Pharmaceuticals Inc: Private sale, May 2023 × Investors in this round 38 investors had bought by the notice of May 22, 2023: 38 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $35 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $1,227,961
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Bryan Smith · Executive Officer David-Alexandre Gros · Executive Officer, Director Paul Little · Executive Officer Steven Perrin · Executive Officer, Director Gary Lyons · Director Jan Hillson · Director John McBride · Director June Lee · Director Keith Katkin · Director Walter Ogier · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, Florida Sold in CA, DE, FL, ID, NH, NJ, NV, NY, TX, and outside the US SVB Securities LLC (CRD 39011) · Boston, Massachusetts Sold in all US states, and outside the US Remarks in the notice On the amounts: “$35M of common stock sold in initial closing; plus $45M assuming exercise of all common warrants issued in initial closing; and $46.7M and $58.3M upon sale of common stock issuable in 2nd and 3rd closings, upon the satisfaction of specified conditions.”Signed by Paul Little, Chief Financial Officer. Newest notice filed May 22, 2023. Read the notice at the SEC .
equity, options SEC Sep 2020 $108 M Private placement after listing $50 to $250 million 35
Tokai Pharmaceuticals Inc: Private sale, Sep 2020 × Investors in this round 35 investors had bought by the notice of Sep 25, 2020: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $108 M of $108 M offered
Smallest investment taken $498
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $4,123,597
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David-Alexandre Gros · Executive Officer, Director Jon N. Kuwahara · Executive Officer Gary A. Lyons · Director John A. McBride · Director Keith A. Katkin · Director Steven N. Perrin · Director Walter A. Ogier · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, Florida Sold in AL, CA, FL, NV, NY, TX, and outside the US SVB Leerink LLC (CRD 39011) · Boston, Massachusetts Sold in all US states Signed by David-Alexandre Gros, Chief Executive Officer. Newest notice filed Sep 25, 2020. Read the notice at the SEC .
equity SEC May 2013 $20 M No. 3 $10 to $50 million 19
Tokai Pharmaceuticals Inc: Raise no. 3, May 2013 × Investors in this round 19 investors had bought by the notice of May 15, 2013: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $20 M of $36 M offered; $16 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jodie P. Morrison · Executive Officer Campbell A. Murray · Director David A. Kessler · Director Joseph A. Yanchik, III · Director Reinhard J. Ambros · Director Seth L. Harrison · Director Timothy J. Barberich · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Jodie P. Morrison, Chief Executive Officer. Newest notice filed May 15, 2013. Read the notice at the SEC .
equity SEC Sep 2011 $2 M No. 2 Under $2 million 6
Tokai Pharmaceuticals Inc: Raise no. 2, Sep 2011 × Investors in this round 6 investors had bought by the notice of Sep 20, 2011: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $23 M offered; $21 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Seth L. Harrison · Executive Officer, Director Campbell A. Murray · Director David A. Kessler · Director Joseph A. Yanchik, III · Director Reinhard A. Ambros · Director Timothy A. Barberich · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Cindy Driscoll, Director of Finance and Administration. Newest notice filed Sep 20, 2011. Read the notice at the SEC .
equity SEC May 2009 $10 M No. 1 $10 to $50 million 10
Tokai Pharmaceuticals Inc: Raise no. 1, May 2009 × Investors in this round 10 investors had bought by the notice of May 6, 2009: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $22 M offered; $12 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in De People named in the notice Scott Chappel · Executive Officer Seth L. Harrison · Executive Officer, Director Campbell Murray · Director David Kessler · Director Joseph A. Yanchik, III · Director Reinhard Ambros · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Seth L. Harrison, Chief Executive Officer. Newest notice filed May 6, 2009. Read the notice at the SEC .
equity SEC